Casdin Capital’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $12.5M | Sell |
890,000
-100,000
| -10% | -$1.4M | 1.13% | 15 |
|
|
2025
Q1 | $13.5M | Hold |
990,000
| – | – | 1.1% | 17 |
|
|
2024
Q4 | $20.2M | Hold |
990,000
| – | – | 1.34% | 17 |
|
|
2024
Q3 | $28.8M | Sell |
990,000
-310,000
| -24% | -$9.03M | 1.92% | 14 |
|
|
2024
Q2 | $30.2M | Hold |
1,300,000
| – | – | 2.3% | 12 |
|
|
2024
Q1 | $26.7M | Hold |
1,300,000
| – | – | 1.98% | 17 |
|
|
2023
Q4 | $27.9M | Hold |
1,300,000
| – | – | 2.74% | 14 |
|
|
2023
Q3 | $26.8M | Hold |
1,300,000
| – | – | 2.97% | 13 |
|
|
2023
Q2 | $38.4M | Hold |
1,300,000
| – | – | 3.35% | 12 |
|
|
2023
Q1 | $30M | Hold |
1,300,000
| – | – | 2.47% | 15 |
|
|
2022
Q4 | $36.2M | Buy |
1,300,000
+305,000
| +31% | +$8.48M | 2.8% | 11 |
|
|
2022
Q3 | $30.5M | Sell |
995,000
-505,000
| -34% | -$15.5M | 2.01% | 15 |
|
|
2022
Q2 | $44.1M | Hold |
1,500,000
| – | – | 3.73% | 12 |
|
|
2022
Q1 | $48.3M | Hold |
1,500,000
| – | – | 2.16% | 17 |
|
|
2021
Q4 | $66.9M | Sell |
1,500,000
-200,000
| -12% | -$8.92M | 1.89% | 18 |
|
|
2021
Q3 | $85.8M | Buy |
1,700,000
+90,000
| +6% | +$4.54M | 2.13% | 17 |
|
|
2021
Q2 | $126M | Hold |
1,610,000
| – | – | 3.21% | 10 |
|
|
2021
Q1 | $91.9M | Buy |
1,610,000
+300,000
| +23% | +$17.1M | 2.74% | 12 |
|
|
2020
Q4 | $110M | Hold |
1,310,000
| – | – | 3.25% | 9 |
|
|
2020
Q3 | $46.9M | Hold |
1,310,000
| – | – | 2.1% | 15 |
|
|
2020
Q2 | $31.7M | Sell |
1,310,000
-145,000
| -10% | -$3.51M | 1.87% | 18 |
|
|
2020
Q1 | $25.5M | Buy |
1,455,000
+205,000
| +16% | +$3.59M | 2.7% | 15 |
|
|
2019
Q4 | $21.8M | Buy |
1,250,000
+600,000
| +92% | +$10.5M | 2% | 16 |
|
|
2019
Q3 | $9.96M | Buy |
650,000
+250,000
| +63% | +$3.83M | 1.03% | 25 |
|
|
2019
Q2 | $8.3M | Buy |
400,000
+300,000
| +300% | +$6.23M | 0.78% | 27 |
|
|
2019
Q1 | $2.32M | Hold |
100,000
| – | – | 0.26% | 29 |
|
|
2018
Q4 | $2.07M | Buy |
+100,000
| New | +$2.07M | 0.35% | 29 |
|